Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens

AIMS: To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction ≤35%). METHODS AND RESULTS: A 5‐day open‐label run‐in (sacubitril/valsartan 50 mg twice daily) pre...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Heart Fail
Päätekijät: Senni, Michele, McMurray, John J.V., Wachter, Rolf, McIntyre, Hugh F., Reyes, Antonio, Majercak, Ivan, Andreka, Peter, Shehova‐Yankova, Nina, Anand, Inder, Yilmaz, Mehmet B., Gogia, Harinder, Martinez‐Selles, Manuel, Fischer, Steffen, Zilahi, Zsolt, Cosmi, Franco, Gelev, Valeri, Galve, Enrique, Gómez‐Doblas, Juanjo J., Nociar, Jan, Radomska, Maria, Sokolova, Beata, Volterrani, Maurizio, Sarkar, Arnab, Reimund, Bernard, Chen, Fabian, Charney, Alan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2016
Aiheet:
Medical Treatment
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084812/
https://ncbi.nlm.nih.gov/pubmed/27170530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.548
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia